Application of immune checkpoint inhibitors in the treatment of small cell lung cancer
10.3760/cma.j.cn371439-20210305-00148
- VernacularTitle:免疫检查点抑制剂在小细胞肺癌治疗中的应用
- Author:
Chun CAO
1
;
Wenqi HE
;
Jun YAN
Author Information
1. 四川省自贡市第一人民医院肿瘤科 643000
- Keywords:
Small cell lung carcinoma;
Immune checkpoint inhibitors;
PD-1;
PD-L1;
CTLA-4
- From:
Journal of International Oncology
2021;48(12):747-750
- CountryChina
- Language:Chinese
-
Abstract:
The emergence of immune checkpoint inhibitors (ICIs) have changed the pattern of anti-tumor therapy and brought new hope to the treatment of small cell lung cancer (SCLC). Currently, ICIs are most widely studied mainly include programmed death-1/ligand-1 and cytotoxic T-lymphocyte antigen-4. Altezumab is recommended for the first-line treatment of extensive SCLC, while pebrizizumab is recommended for the third-line treatment of extensive SCLC. There has been no breakthrough in the second-line and maintenance treatment of SCLC with ICIs.
